Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Transcode Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −1 vs. Q3 2021
- Shares held
- 2.35M
- −81.7K (−3.4%) vs. Q3 2021
- Total value
- $5.98M
- −$1.30M (−17.9%) vs. Q3 2021
- New holders
- 4
- 6 more added
- Sold out
- 5
- 1 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RNAZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $208.1K |
| Q1 2026 | 8 | $265.7K |
| Q4 2025 | 6 | $26.4K |
| Q3 2025 | 8 | $155.0K |
| Q2 2025 | 9 | $237.0K |
| Q1 2025 | 19 | $1.06M |
| Q4 2024 | 5 | $33.4K |
| Q3 2024 | 10 | $185.8K |
| Q2 2024 | 15 | $263.0K |
| Q1 2024 | 7 | $284.1K |
| Q4 2023 | 13 | $105.4K |
| Q3 2023 | 11 | $281.6K |
| Q2 2023 | 5 | $476.6K |
| Q1 2023 | 11 | $88.6K |
| Q4 2022 | 18 | $222.5K |
| Q3 2022 | 13 | $2.27M |
| Q2 2022 | 13 | $2.67M |
| Q1 2022 | 13 | $3.14M |
| Q4 2021 | 16 | $5.98M |
| Q3 2021 | 17 | $7.28M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Transcode Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 1,270,600 | $3.23M | 1.01% | +1000.0% | Added |
| Kepos Capital LP | 300,000 | $762.0K | 0.06% | 00.0% | Unchanged |
| Worth Venture Partners, LLC | 295,540 | $751.0K | 0.37% | +220.0% | Added |
| Vanguard Group Inc | 200,117 | $508.0K | 0.00% | 00.0% | Unchanged |
| Redmond Asset Management, LLC | 88,010 | $224.0K | 0.06% | +88,010 | New |
| Geode Capital Management, LLC | 71,272 | $181.0K | 0.00% | +54,249+318.7% | Added |
| ACT Capital Management, LLC | 50,000 | $127.0K | 0.09% | 00.0% | Unchanged |
| State Street Corp | 20,600 | $52.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 16,796 | $43.0K | 0.00% | +430+2.6% | Added |
| K.J. Harrison & Partners Inc | 16,000 | $41.0K | 0.01% | +16,000 | New |
| Shay Capital LLC | 15,060 | $38.0K | 0.01% | 00.0% | Unchanged |
| UBS Group AG | 5,254 | $13.0K | 0.00% | −83−1.6% | Reduced |
| Tower Research Capital LLC (TRC) | 2,329 | $6.00K | 0.00% | +856+58.1% | Added |
| High Net Worth Advisory Group LLC | 2,500 | $6.00K | 0.00% | +2,500 | New |
| Wells Fargo & Company | 41 | $0 | 0.00% | +3+7.9% | Added |
| Royal Bank of Canada | 49 | $0 | 0.00% | +49 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −90,774−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −76,645−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −33,314−100.0% | Sold out |
| National Asset Management, Inc. | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −18,064−100.0% | Sold out |